Amgen Announces Top-Line Results Of Trial To Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) In CKD Patients With Type-2 Diabetes
Links shared publicly online about this topic.
- 1,795total visits
Amgen Announces Top-Line Results Of Trial To Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) In CKD Patients With Type-2 Diabetes
Amgen (nasdaq: amgn) announced that in a large, randomized, double-blind, placebo-controlled, phase 3 study of patients with chronic kidney disease (ckd) (not requiring dialysis), anemia and type
View full resource at medicalnewstoday.com
Tags: Urinary System, Kidney Disease, Dialysis, End-Stage Renal Disease, Disease and Condition, Phase 3 Clinical Trial, Amgen, Nephrology
Most Recently Shared on August 26, 2009 at 12:44 pm By:
Amgen Announces Top-Line Results Of Trial To Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) In CKD.. http://bit.ly/8yOKl
Advertisement
